Cantor Fitzgerald Has Weak Estimate for DRUG FY2025 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for Bright Minds Biosciences in a note issued to investors on Monday, December 1st. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings of ($1.94) per share for the year, down from their prior forecast of ($1.93). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.24) per share. Cantor Fitzgerald also issued estimates for Bright Minds Biosciences’ FY2026 earnings at ($6.99) EPS.

Several other equities research analysts have also recently issued reports on the company. Chardan Capital upgraded Bright Minds Biosciences to a “strong-buy” rating in a report on Wednesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $85.00 target price on shares of Bright Minds Biosciences in a research report on Monday, September 15th. Wall Street Zen lowered Bright Minds Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd. BTIG Research assumed coverage on shares of Bright Minds Biosciences in a research note on Monday, September 8th. They set a “buy” rating and a $72.00 price objective for the company. Finally, Zacks Research lowered shares of Bright Minds Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $82.50.

Bright Minds Biosciences Stock Performance

DRUG stock opened at $72.50 on Wednesday. The company has a 50 day moving average price of $60.45 and a two-hundred day moving average price of $43.53. The stock has a market capitalization of $564.78 million, a P/E ratio of -77.96 and a beta of -6.22. Bright Minds Biosciences has a one year low of $23.17 and a one year high of $75.99.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DRUG. Police & Firemen s Retirement System of New Jersey purchased a new stake in Bright Minds Biosciences during the second quarter worth approximately $28,000. JPMorgan Chase & Co. lifted its holdings in shares of Bright Minds Biosciences by 624.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,173 shares of the company’s stock valued at $57,000 after acquiring an additional 1,873 shares in the last quarter. Russell Investments Group Ltd. acquired a new position in shares of Bright Minds Biosciences during the 3rd quarter valued at $58,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Bright Minds Biosciences during the 2nd quarter worth $66,000. Finally, Gordian Capital Singapore Pte Ltd acquired a new stake in Bright Minds Biosciences in the 3rd quarter valued at $73,000. 40.52% of the stock is owned by institutional investors and hedge funds.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.